Letromal

Letrozole, the active ingredient in Letromal, is an aromatase inhibitor presented as an oral tablet for oral use. It is used to treat hormone receptor‑positive breast cancer in postmenopausal women by lowering estrogen production. GNH USA supplies Letromal as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Letrozole is an aromatase inhibitor indicated for hormone‑dependent breast cancer and related endocrine therapy pathways. - Hormone receptor‑positive breast cancer in postmenopausal women: reduces estrogen‑driven tumor growth and helps prevent disease progression. - Adjuvant therapy after primary surgery: lowers the risk of cancer recurrence when used as part of postoperative treatment. - Metastatic breast cancer in postmenopausal patients: provides disease control by sustained estrogen suppression.

Letrozole may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Hot flashes: transient episodes of increased skin temperature. - Arthralgia: joint pain or stiffness. - Fatigue: general feeling of tiredness. - Nausea: mild to moderate upset stomach. - Headache: occasional mild headache. - Bone mineral density loss: gradual reduction in bone density.

Serious or Rare Side Effects: - Venous thromboembolism: blood clot formation in veins. - Severe liver injury: marked elevation of liver enzymes or hepatic failure. - Interstitial lung disease: inflammation of lung tissue. - Myocardial infarction: rare heart attack events. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Osteoporotic fractures: increased risk of bone fractures due to weakened bones.

Before initiating Letrozole therapy, consider the following safety measures. - Pregnancy risk: contraindicated in pregnancy; ensure effective contraception for women of childbearing potential. - Bone health: monitor bone mineral density and consider calcium/vitamin D supplementation. - Liver function: assess hepatic function periodically, especially in patients with pre‑existing liver disease. - Cardiovascular status: evaluate cardiovascular risk factors, as estrogen depletion may affect lipid profiles. - Drug interactions: review concomitant medications for potential interactions that may alter letrozole levels. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Letrozole can interact with several medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP2A6 inhibitors (e.g., ketoconazole): may increase letrozole plasma concentrations. - Estrogen‑containing hormone therapy: antagonizes therapeutic effect. - Tamoxifen: concurrent use reduces efficacy of both agents.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect; monitor INR. - Simvastatin: potential increase in statin levels; observe for myopathy. - SSRIs (e.g., fluoxetine): may affect hepatic metabolism; watch for altered letrozole exposure.